摘要
目的观察阿仑膦酸钠片(默沙东公司)治疗早期激素继发性股骨头坏死的临床疗效。方法将64例确诊为早期激素继发性股骨头坏死患者,分为治疗组32例和对照组32例。对照组口服骨舒康胶囊(辽宁康辰药业有限公司)4粒/次,2次/天,碳酸钙D3片(钙尔奇,惠氏制药有限公司)600毫克/次,1次/天,治疗组在对照组基础上,加服阿仑膦酸钠片(默沙东公司,70毫克/片)70毫克/次,1次/周,治疗周期为6个月,观察治疗3、6个月后,两组间疗效、疼痛评分(VAS评分)、股骨头CT片及药物不良反应情况。结果治疗3个月后,两组间疗效、疼痛评分(VAS评分)有显著差异性(P<0.05)。两组间股骨头CT片、药物不良反应比较,无显著差异性(P>0.05)。治疗6个月后,两组间疗效、疼痛评分(VAS评分)有显著差异性(P<0.05))。两组间股骨头CT片比较,治疗组明显优于对照组,具有显著差异性(P<0.05)。两组间药物不良反应,无显著差异性(P>0.05)。结论应用阿仑膦酸钠,能显著改善激素继发性股骨头坏死患者的临床症状及股骨头影像学,且无显著不良反应,值得临床推荐应用。
Objective To observe the clinical efficacy of early glucocorticoids secondary femoral head avascular necrosis treated by alendronate tablet （Merck）. Methods 64 cases diagnosed with early glucocorticoids secondary femoral head avascular necrosis patients, 32 cases were divided into treatment group and the control group of 32 patients.The control group was treated with GuShukang capsule （Liao Ning Kangchen Pharmaceutical Co., Ltd.） 4/times, 2 times/day, calcium D3 tablets （Caltrate, Wyeth Pharmaceuticals） 600 mg/times, 1 time/day, In the control group, the treatment group on the basis of additional services alendronate tablet （Merck, 70 mg/tablets） 70 mg/times, 1 times/week, treatment period of 6 months, observation and treatment three months, six months later, the two groups were accessed by pain scores（VAS score）, femoral head CT slices and adverse drug reactions. Results After 3 months of treatment, the efficacy of the two groups, pain scores （VAS score） had significant differences （P〈0.05）. Between the two groups of the femoral head CT slices, adverse drug reactions compared with no significant difference （P〉0.05）. Conclusion Alendronate, can significantly improve the hormone secondary osteonecrosis of the femoral head in patients with clinical symptoms and imaging, and no significant adverse effects, worthy of clinical application is recommended.
出处
《中国医药指南》
2016年第21期20-21,共2页
Guide of China Medicine
关键词
阿仑膦酸钠
早期
激素继发性股骨头坏死
临床观察
Alendronate
Early
Glucocorticoids secondary femoral head avascular necrosis
Clinical observation
